Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL633836 | 1.00 | — | — | |
| SCHEMBL190387 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL9031347 | 0.94 | SMN1; SMN2 (0.32) | DPP7SMN1; SMN2 | |
| SCHEMBL20908243 | 0.90 | — | — | |
| SCHEMBL7142061 | 0.83 | CYP2D6 (0.32) | DPP7CYP2D6 | |
| SCHEMBL20661653 | 0.83 | — | — | |
| SCHEMBL179841 | 0.83 | CYP2D6 (0.32) | DPP7CYP2D6 | |
| SCHEMBL3416020 | 0.83 | — | — | |
| SCHEMBL20657386 | 0.80 | — | — | |
| SCHEMBL2412914 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154766-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2022-01-04 | — | — | US | disclosed |
| US-20210032195-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | ELI LILLY AND COMPANY | 2021-02-04 | — | — | US | disclosed |
| US-10377717-B2 | Farnesoid X receptor agonists and uses thereof | METACRINE, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| US-20120094986-A1 | ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-04-19 | — | — | US | disclosed |
| WO-2012038904-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-03-29 | — | — | WO | disclosed |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI (FR) | 2012-03-01 | — | — | US | disclosed |
| EP-2411364-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| EP-2411367-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| EP-2411368-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI (FR) | 2012-02-01 | — | — | EP | disclosed |
| WO-2010109115-A1 | ANTICANCER COMPOUNDS, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109122-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010109123-A1 | ANTICANCER DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210032195-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | DPP7 1036/4885FDPS 46/4885SMN1; SMN2 4590/4885 |
| US-11214538-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | DPP7 1036/4885FDPS 46/4885SMN1; SMN2 4590/4885 |
| US-20120053170-A1 | NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS | NAMPT, NNT, NQO1 | DPP7 1947/4885FDPS 127/4885SMN1; SMN2 1569/4885 |
| US-20120094986-A1 | ANTICANCER DERIVIATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | NAMPT, NQO1, NNT | DPP7 1107/4885FDPS 184/4885SMN1; SMN2 2714/4885 |
| US-10377717-B2 | Farnesoid X receptor agonists and uses thereof | NR1H4, NR1H2, NR1H3 | DPP7 1036/4885FDPS 46/4885SMN1; SMN2 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.